TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,270,473 | -32.4% | 813,252 | +16.2% | 0.00% | -33.3% |
| Q2 2023 | $10,752,031 | -13.1% | 700,002 | +27.2% | 0.00% | 0.0% |
| Q1 2023 | $12,379,755 | +5.7% | 550,456 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $11,706,896 | +8.6% | 556,676 | +27.2% | 0.00% | 0.0% |
| Q3 2022 | $10,783,000 | -10.9% | 437,586 | -12.4% | 0.00% | -25.0% |
| Q2 2022 | $12,103,000 | +17.6% | 499,486 | +25.1% | 0.00% | +33.3% |
| Q1 2022 | $10,292,000 | -35.1% | 399,357 | -21.9% | 0.00% | -25.0% |
| Q4 2021 | $15,868,000 | +1669.0% | 511,201 | +1282.7% | 0.00% | – |
| Q3 2021 | $897,000 | +80.5% | 36,972 | +8.4% | 0.00% | – |
| Q2 2021 | $497,000 | -94.9% | 34,104 | -91.3% | 0.00% | -100.0% |
| Q1 2021 | $9,765,000 | +1088.0% | 391,091 | +1196.6% | 0.00% | – |
| Q4 2020 | $822,000 | – | 30,163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |